# US 2010/0166649 A1 · Method to inhibit cancer targeting cd24

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0166649 A1
- Document ID: US20100166649A1
- Status: Published application
- Kind: A1
- Application number: 12/307,108
- Filed: 2007-07-02
- Published: 2010-07-01
- Earliest claimed: 2006-06-30
- Assignees: Snu R&Db Foundation
- Inventors: Young Kee Shin
- Web page: https://patentgrep.com/patent/US20100166649A1

## CPC

- A61K 38/178: {Lectin superfamily, e.g. selectins}
- A61K 47/6809: {Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin}
- A61K 47/6813: {the drug being a peptidic cytokine, e.g. an interleukin or interferon}
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 49/0008: {Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure}
- A61K 51/1027: {against receptors, cell-surface antigens or cell-surface determinants}
- A61P 35/00: Antineoplastic agents
- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- C12N 15/1138: {against receptors or cell surface proteins}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/505: {comprising antibodies}
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/734: Complement-dependent cytotoxicity [CDC]
- C12N 2310/14: interfering nucleic acids [NA]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to a method to inhibit cancer by targeting CD24, more precisely a method to inhibit cancer by using CD24 expressed in most cancer cells as a target of an antibody therapeutic agent or by inhibiting the interaction between CD24 and P-selectin. CD24 is over-expressed in most cancer cells and CD24 accumulated in cytoplasm accelerates metastasis. Therefore, the method to inhibit cancer of the invention by targeting CD24 can be effectively used for the treatment of cancer by inhibiting the progress of various cancers over-expressing CD24.

## Claims

### Claim 1

A method of inhibiting cancer overexpressing CD24 comprising
administrating a therapeutically effective amount of anti-CD24 antibody to a subject having cancer.

### Claim at position 2

2-3. (canceled)

### Claim 4 (depends on 1)

The method according to claim 1, wherein the antibody is prepared specifically using the amino acid sequence represented by SEQ. ID. NO: 5 of CD24 sequence represented by SEQ. ID. NO: 7, a part of the sequence or the amino acid sequence and its adjacent sequence along with its glycosylated sequence as an epitope.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the antibody has complement dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the cancer over-expressing CD24 is ovarian cancer, breast cancer, small cell lung cancer, prostatic cancer, pancreatic cancer, rectal cancer, bladder cancer, liver cancer, small intestine cancer, large intestine cancer, cervical cancer or cholangiocarcinoma.

### Claim at position 6

7-24. (canceled)

### Claim 25

A method of inhibiting cancer overexpressing CD24 comprising
co-administrating a therapeutically effective amount of anti-CD24 antibody and another anticancer agent to a subject having cancer.

### Claim 26 (depends on 25)

The method according to claim 25, wherein another anticancer agent is a chemotherapeutic agent, a radiotherapeutic agent or an immunotherapeutic agent.

### Claim 27 (depends on 26)

The method according to claim 26, wherein the chemotherapeutic agent is one or more compounds selected from the group consisting of ifosfamide, doxorubicin HCL, bleomycin, mitomycin, etoposide, vinblastine, vincristine, vinorelbin, paclitaxel, docetaxel, irinotecan, topotecan, hydroxyurea, cyclophosphamide, melphalan, chlorambucil, carmustine, cisplatin, carboplatin, fluorouracil, capecitabine, gemcitabine, imatinib and goserelin acetate.

### Claim 28 (depends on 26)

The method according to claim 26, wherein the radiotherapeutic agent is a nuclide emitting one or more radioactive rays selected from the group consisting of x-ray, gamma-ray, electron beam, photon, alpha-particle and neutron.

### Claim 29 (depends on 28)

The method according to claim 28, wherein the nuclide is selected from the group consisting I-131, Co-60, Co-57, Ir-192, Ho-166, P-32, V-48, Au-198, Tc-99m, I-125, Dy-165, Re-188, Er-169, Sm-153, Y-90, Pd-109 and Sr-89.

### Claim 30 (depends on 26)

The method according to claim 26, wherein the immunotherapeutic agent is a cytokine or an antigen specific therapeutic antibody.

### Claim 31 (depends on 30)

The method according to claim 30, wherein the cytokine is one or more compounds selected from the group consisting of interleukin-1 (IL-1), IL-2, IL-4, IL-5, IL-6, IL-7, IL-10, IL-12, IL-15, IL-18, CSF-GM, CSF-G, IFN-γ, IFN-α, TNF, TGF-β, FLT-3 ligand and CD40 ligand.

### Claim 32 (depends on 30)

The method according to claim 30, wherein the antigen specific therapeutic antibody is selected from the group consisting of Rituxan, Herceptin, Zevalin, Erbitux, Mylotarg, Campath-1H, Zenapax, Remicade and Enbrel.

### Claim 33 (depends on 25)

The method according to claim 25, wherein the anti-CD24 antibody has complement dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity.

### Claim 34 (depends on 25)

The method according to claim 25, wherein the cancer overexpressing CD24 is ovarian cancer, breast cancer, small cell lung cancer, prostatic cancer, pancreatic cancer, rectal cancer, bladder cancer, liver cancer, small intestine cancer, large intestine cancer, cervical cancer or cholangiocarcinoma.

### Claim 35 (depends on 25)

The method according to claim 25, wherein the anti-CD24 antibody is prepared specifically using the amino acid sequence represented by SEQ. ID. NO: 5 of CD24 sequence represented by SEQ. ID. NO: 7, a part of the sequence or the amino acid sequence and its adjacent sequence along with its glycosylated sequence as an epitope